Relay Therapeutics (RLAY) Change in Account Payables (2019 - 2024)

Relay Therapeutics (RLAY) has 6 years of Change in Account Payables data on file, last reported at -$4.3 million in Q3 2024.

• On a quarterly basis, Change in Account Payables fell 251.88% year-over-year to -$4.3 million in Q3 2024; TTM through Sep 2024 was -$6.4 million, a 228.7% decrease from a year earlier, with the FY2023 full-year figure at -$2.4 million, down 220.36% from the prior year.
• Change in Account Payables for Q3 2024 stood at -$4.3 million, down from $3.2 million in the prior quarter.
• Over the last five years, Change in Account Payables for RLAY reached as high as $4.6 million in Q3 2022 and fell as low as -$5.4 million in Q4 2023.
• Historically, Change in Account Payables has averaged -$46210.5 across 5 years, with a median of -$56000.0 in 2021.
• Across the five-year window, Change in Account Payables surged 1737.5% in 2020 and slumped 5950.0% in 2022, its largest moves.
• Year by year, Change in Account Payables stood at $1.3 million in 2020, then jumped by 89.63% to $2.4 million in 2021, then retreated by 19.15% to $2.0 million in 2022, then plunged by 373.21% to -$5.4 million in 2023, then increased by 19.99% to -$4.3 million in 2024.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$4.3 million in Q3 2024, $3.2 million in Q2 2024, and $102000.0 in Q1 2024.